Suppliers and packagers for forteo

forteo

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318	NDA	Eli Lilly and Company	0002-8400-01	1 SYRINGE in 1 CARTON (0002-8400-01) / 2.24 mL in 1 SYRINGE	2002-11-26
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318	NDA AUTHORIZED GENERIC	Prasco Laboratories	66993-495-28	1 SYRINGE in 1 CARTON (66993-495-28) / 2.24 mL in 1 SYRINGE	2023-11-17

Comprehensive Analysis of Suppliers for the Pharmaceutical Drug Forteo (Teriparatide Injection)

The landscape of suppliers for Forteo (teriparatide injection), a critical osteoporosis treatment, encompasses a diverse network of original manufacturers, generic producers, and distribution partners. As patents expire and regulatory approvals expand, the market has seen increased participation from global pharmaceutical companies and specialized biotech firms. This report examines the key players, pricing structures, regulatory challenges, and emerging trends shaping the supply chain for Forteo and its generic equivalents.

---

Origins and Brand-Name Manufacturing

Eli Lilly and Company’s Role as the Innovator

Eli Lilly and Company developed Forteo (teriparatide injection) and secured FDA approval in 2002[11]. The drug’s initial formulation utilized a multi-dose pen delivery system designed for subcutaneous administration, with Lilly introducing an updated device in 2008 to improve patient usability[4]. As the reference listed drug (RLD) holder, Lilly maintained exclusivity through patents covering formulation and delivery mechanisms, including a key patent (US 7,517,334) for a spring-driven locking feature in the pen device, which expired in March 2025[3].

Lilly’s manufacturing infrastructure supports large-scale production, with annual sales of Forteo reaching $609 million as of July 2023[1]. The company also implemented patient assistance programs, such as the Forteo Savings Card, which reduces out-of-pocket costs to $4 per month for eligible commercially insured U.S. patients[9][10]. However, this program excludes beneficiaries of government-funded healthcare plans, creating disparities in access[10].

---

Emergence of Generic Suppliers

Teva Pharmaceuticals’ Entry into the U.S. Market

Teva Pharmaceuticals gained FDA approval for its generic teriparatide injection in November 2023, leveraging a delivery device licensed from Antares Pharma[1]. As one of the largest generic drug manufacturers globally, Teva’s entry significantly disrupted Forteo’s market dynamics. The company’s approval marked the first direct competition to Lilly’s brand-name product, with Teva’s version priced at a discount to capture cost-sensitive healthcare systems[1][3].

Apotex and Ambio’s Collaborative Generic Launch

In December 2023, Apotex Corp., partnering with Ambio Inc., received FDA approval for another generic teriparatide injection[12][15]. Ambio’s expertise in synthetic peptide development enabled the creation of a bioequivalent product, while Apotex’s distribution network facilitated rapid market entry in the U.S.[12]. The pre-filled pen format, containing 28 daily doses of 20 mcg, mirrors Lilly’s original design, ensuring parity in patient adherence[15].

Global Generic Expansion: Alvogen and Pfenex

Outside the U.S., Alvogen Ltd. and Pfenex Inc. expanded their collaboration in 2019 to commercialize PF708, a therapeutic equivalent to Forteo, across the EU, Middle East, North Africa (MENA), and other regions[6]. The partnership leverages Theramex’s specialty marketing in women’s health and SAJA Pharma’s distribution channels in MENA, illustrating the fragmented yet coordinated nature of global generic supply chains[6].

---

Active Pharmaceutical Ingredient (API) Suppliers

PharmaCompass’s Registry of API Manufacturers

PharmaCompass lists 13 manufacturers and suppliers of teriparatide acetate API, including entities in India, China, and Europe[2][14]. These suppliers must comply with Good Manufacturing Practices (GMP) and hold certifications such as U.S. Drug Master Files (USDMF) or European Certificates of Suitability (CEP)[14]. Pricing for teriparatide API fluctuates based on production scale, regulatory compliance costs, and regional demand, with Indian suppliers like Nexus Lifecare offering pre-filled pens at approximately $220 (₹18,200) per unit[7][13].

Regulatory Oversight of API Production

The FDA mandates rigorous quality controls for API suppliers, particularly for peptides like teriparatide, which require precise synthesis to avoid immunogenic impurities[14]. Manufacturers such as Ambio emphasize advanced analytical methods to characterize impurities, ensuring batch consistency and compliance with bioequivalence standards[12].

---

Distribution Networks and Affordability Programs

Prescription Hope’s Cost-Subsidized Access

For uninsured or underinsured patients in the U.S., Prescription Hope provides Forteo through manufacturer patient assistance programs at a fixed cost of $60 per month[5]. This service negotiates directly with pharmaceutical companies to bridge affordability gaps, though it excludes government-funded beneficiaries like Medicare enrollees[5].

International Pricing Disparities

In markets like India, Forteo is available at significantly lower prices compared to the U.S., with generic versions priced as low as $60 (₹5,000) per pen[7]. Conversely, Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) rejected subsidizing Forteo due to insufficient clinical data, limiting access despite Lilly’s appeals[8].

---

Regulatory and Patent Challenges

Patent Litigation and Market Exclusivity

Lilly’s strategic patenting of delivery devices extended Forteo’s market exclusivity beyond the core compound patent expiration. The 2009 patent (US 7,517,334) on the pen’s locking mechanism delayed generic entry until 2025[3]. Generic suppliers like Teva and Apotex had to redesign their delivery systems or license existing technologies to circumvent these protections[1][12].

Bioequivalence and Interchangeability Hurdles

The FDA’s requirement for bioequivalence studies in ANDA submissions complicates generic Approval. Ambio’s teriparatide injection, for instance, underwent extensive comparative testing to demonstrate pharmacokinetic equivalence to Forteo[12]. These studies add to development costs but are critical for regulatory greenlighting.

---

Emerging Suppliers and Market Dynamics

Indian Pharmaceutical Exporters

Indian manufacturers, including Bighope Impex and Skavis Biotec, export teriparatide injections to the U.S., U.K., and Africa at competitive prices[7][13]. Their proliferation highlights the role of emerging markets in pressuring global drug prices downward, though quality concerns persist among regulators[7].

Biosimilar and Novel Peptide Developers

Ambio’s pipeline includes biosimilar peptides targeting diabetes and obesity, signaling a shift toward complex generics beyond osteoporosis[15]. Such innovations may further diversify the supplier base, reducing reliance on traditional generics.

---

Conclusion

The supplier ecosystem for Forteo reflects broader trends in pharmaceutical globalization, patent strategizing, and regulatory pragmatism. While Eli Lilly dominated the market for over two decades, generic entrants like Teva and Apotex are democratizing access through competitive pricing. Ongoing challenges, such as API quality control and regional reimbursement policies, will shape the drug’s availability in coming years. Healthcare providers must navigate these dynamics to optimize patient outcomes amid evolving cost and supply considerations.

---

Key Takeaways

1. Brand-Name Dominance: Eli Lilly’s Forteo remains the reference product, supported by patient assistance programs and device patents expiring in 2025[9][3].
2. Generic Disruption: Teva and Apotex/Ambio have introduced lower-cost generics in the U.S., with more entrants expected post-2025[1][12].
3. Global Supplier Networks: Indian and Chinese API manufacturers play pivotal roles in reducing production costs, though quality oversight is critical[7][14].
4. Affordability Programs: Subsidized access initiatives like Prescription Hope aid uninsured patients but exclude government beneficiaries[5][10].
5. Regulatory Hurdles: Bioequivalence requirements and patent litigation delay generic market entry, impacting pricing and availability[3][12].

---

FAQs
1. What distinguishes Forteo’s delivery device from generic versions?
Lilly’s patented pen design includes a locking mechanism to prevent post-final-dose use, while generics use alternative designs or license existing technologies[3][4].

2. Are FDA-approved Forteo generics available outside the U.S.?
Yes; Alvogen and Pfenex supply PF708 in the EU and MENA, though Lilly’s Forsteo retains market share in some regions[6][8].

3. How do Indian suppliers price Forteo compared to U.S. generics?
Indian generic versions cost ~$60–$220 per pen versus ~$900 for brand-name Forteo in the U.S., reflecting lower production and regulatory costs[7][13].

4. Can Medicare patients access the Forteo Savings Card?
No; Lilly’s program excludes all government-funded healthcare recipients, necessitating alternative subsidies or generics[9][10].

5. What role do peptide specialists like Ambio play in the generic market?
Ambio’s synthetic peptide expertise enables bioequivalent complex generics, expanding access while maintaining therapeutic efficacy[12][15].

References

1. https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2023/Teva-Announces-Approval-of-a-Generic-Version-of-Forteo-teriparatide-injection-in-the-U.S/default.aspx
2. https://www.pharmacompass.com/listed-active-pharmaceutical-ingredients/forteo
3. https://www.drugs.com/availability/generic-forteo.html
4. https://investor.lilly.com/news-releases/news-release-details/lilly-launches-new-forteo-delivery-device
5. https://prescriptionhope.com/medication/forteo-teriparatide/
6. https://www.globenewswire.com/news-release/2019/02/28/1744291/0/en/Pfenex-and-Alvogen-Expand-Development-and-Commercialization-Collaboration-for-PF708-a-Therapeutic-Equivalent-Candidate-to-Forteo-Forsteo-to-the-EU-MENA-and-ROW.html
7. https://dir.indiamart.com/impcat/forteo-injections.html
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC1828316/
9. https://forteo.lilly.com
10. https://forteo.lilly.com/hcp
11. https://medical.lilly.com/us/products/answers/what-are-the-approved-indications-for-forteo-teriparatide-injection-36766
12. https://www.ambiorx.com/news/ambio-announces-us-fda-approval-of-a-generic-version-of-forteo-teriparatide-injection-for-its-partner-apotex/
13. https://www.indiamart.com/proddetail/forteo-injection-teriparatide-7256462248.html
14. https://www.pharmacompass.com/manufacturers-suppliers-exporters/forteo
15. https://www.pharmaceutical-technology.com/news/fda-ambio-osteoporosis/